The developing landscape of diabetes treatment is experiencing a exciting shift, driven by innovative incretin-based therapies. At this time, semaglutide has achieved considerable attention, but competing medications like tirzepatide, retatrutide, and cagrilintide are set to reshape the future. Tirzepatide, a dual GIP and GLP-1 site agonist, del… Read More